Treatment of myelitis in Behçet's disease with rituximab

Maria J osè Messina, Mariaemma Rodegher, Roberta Scotti, Vittorio Martinelli

Research output: Contribution to journalArticlepeer-review


Behçet's disease (BD) is a chronic inflammatory disorder that involves the parenchymal central nervous system (neuro-BD, NBD) approximately in 5-49% of patients, causing lesions rarely located in the spinal cord (SC). We report the first case of NBD-myelitis treated with intravenous rituximab. A 41-year-old man affected by BD presented with mild paraparesis with a miliary involvement and a 'net-like' gadolinium enhancement (Gde) of the SC. After a therapeutic attempt with pulsed cyclophosphamide and intravenous methylprednisolone, the clinical and neuroradiological course worsened. A progressive improvement was observed after rituximab administration associated with low doses of oral prednisone. No disease activity was detected and the patient reported no adverse event. After six rituximab cycles, cervical MRI was normal while thoracic MRI showed a slight T2-weighted hyperintensity of D4-D10 spinal tract without Gde. A combined use of rituximab and oral steroids resulted in a long-term suppression of NBD activity without any safety concern.

Original languageEnglish
JournalBMJ Case Reports
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Treatment of myelitis in Behçet's disease with rituximab'. Together they form a unique fingerprint.

Cite this